96 related articles for article (PubMed ID: 29911750)
1. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
2. The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma.
Shendy K; Abdelkawy K; Ali AA; Belal F; Abdelhakiem M; Magdy G; Anber N; Elbarbry F
Xenobiotica; 2024 Feb; 54(2):95-105. PubMed ID: 38381003
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the
Guo Q; Sun JL; Li R; Li X
Int J Gen Med; 2024; 17():1221-1231. PubMed ID: 38559593
[TBL] [Abstract][Full Text] [Related]
4. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.
Holmboe L; Andersen AM; Mørkrid L; Slørdal L; Hall KS
Br J Clin Pharmacol; 2012 Jan; 73(1):106-14. PubMed ID: 21707700
[TBL] [Abstract][Full Text] [Related]
5. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
[TBL] [Abstract][Full Text] [Related]
7. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
Reiss SN; Buie LW; Adel N; Goldman DA; Devlin SM; Douer D
Ann Hematol; 2016 Dec; 95(12):2009-2015. PubMed ID: 27542957
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Chen X; Li J; Yu L; Hu W; Cai J; Wang Z; Chen C; Zhang X; Xie Y; Wu K; Mo Y; Chen J; Shen S
Br J Haematol; 2024 Apr; 204(4):1354-1366. PubMed ID: 38432257
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with high-dose methotrexate induced toxicities.
Li W; Mo J; Yang Z; Zhao Z; Mei S
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):263-274. PubMed ID: 38501267
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors.
Campagne O; Huang J; Lin T; Reddick WE; Selvo NS; Onar-Thomas A; Ward D; Robinson G; Gajjar A; Stewart CF
Eur J Pharm Sci; 2024 Feb; 193():106669. PubMed ID: 38070781
[TBL] [Abstract][Full Text] [Related]
11. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.
Taylor ZL; Miller TP; Poweleit EA; DeGroote NP; Pommert L; Awoniyi O; Board SG; Ugboh N; Joshi V; Ambrosino N; Chavana A; Bernhardt MB; Schafer ES; O'Brien MM; Castellino SM; Ramsey LB
Clin Transl Sci; 2023 Nov; 16(11):2130-2143. PubMed ID: 37503924
[TBL] [Abstract][Full Text] [Related]
12. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.
Larkin T; Kashif R; Elsayed AH; Greer B; Mangrola K; Rafiee R; Nguyen N; Shastri V; Horn B; Lamba JK
JCO Precis Oncol; 2023 Mar; 7():e2200580. PubMed ID: 36952646
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Gut Microbiota Changes on Methotrexate-Induced Neurotoxicity in Developing Young Rats.
Chen YC; Hou CY; Hsu MH; Huang LT; Hsiao CC; Sheen JM
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672262
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate Toxicity in Dermatological Patients.
Ayén-Rodríguez Á; Gil-Villalba A; Ruiz-Villaverde R; Navarro-Triviño FJ
Actas Dermosifiliogr; 2024 Feb; ():. PubMed ID: 38373610
[No Abstract] [Full Text] [Related]
15. [[Translated article]]Methotrexate Toxicity in Dermatological Patients.
Rodríguez ÁA; Villalba AG; Villaverde RR; Navarro-Triviño FJ
Actas Dermosifiliogr; 2024 May; ():. PubMed ID: 38815680
[No Abstract] [Full Text] [Related]
16. The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis.
Yao P; He X; Zhang R; Tong R; Xiao H
Hematology; 2019 Dec; 24(1):10-19. PubMed ID: 30024839
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
18. Association of
Razali RH; Noorizhab MNF; Jamari H; James RJ; Teh KH; Ibrahim HM; Teh LK; Salleh MZ
Pediatr Hematol Oncol; 2020 Apr; 37(3):185-197. PubMed ID: 31870219
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.
Esmaili MA; Kazemi A; Faranoush M; Mellstedt H; Zaker F; Safa M; Mehrvar N; Rezvany MR
Iran J Basic Med Sci; 2020 Jun; 23(6):800-809. PubMed ID: 32695297
[TBL] [Abstract][Full Text] [Related]
20. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.
Frosst P; Blom HJ; Milos R; Goyette P; Sheppard CA; Matthews RG; Boers GJ; den Heijer M; Kluijtmans LA; van den Heuvel LP
Nat Genet; 1995 May; 10(1):111-3. PubMed ID: 7647779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
